Asegua Therapeutics
Pre-clinicalAsegua Therapeutics is providing access to hepatitis C therapies with two new drugs: authorized generic of HARVONI® (ledipasvir/sofosbuvir) and authorized generic of EPCLUSA® (sofosbuvir/velpatasvir).
Founded
2018
Focus
Generic Drugs
About
Asegua Therapeutics is providing access to hepatitis C therapies with two new drugs: authorized generic of HARVONI® (ledipasvir/sofosbuvir) and authorized generic of EPCLUSA® (sofosbuvir/velpatasvir).
Company Info
TypePrivate
Founded2018
LocationCambridge, United States
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile